Compare Amphastar Pharmaceuticals Inc (AMPH) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Teradyne, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Teradyne, Inc. trades at $380.76 (market cap $57.08B). The key difference: Teradyne, Inc. is far larger — about 66.1× Amphastar Pharmaceuticals Inc's market cap, and Teradyne, Inc. pays a 0.14% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | TER | |
|---|---|---|
Market Cap | $863.95M | $57.08B |
Sector | Health | Technology |
52-Week High | $30.81 | $483.84 |
52-Week Low | $16.87 | $104.68 |
Enterprise Value | $1.26B | $56.83B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Teradyne (TER) trades at $379.31, down 1.45% today but maintains strong technical momentum with a bullish moving average signal. The company demonstrates robust fundamentals with record Q2 2026 earnings of $2.47 EPS beating estimates by 18%, driven by AI-led semiconductor test demand. Revenue grew to $3.19 billion in 2025 with impressive 25.77% net income margin and 36.66% ROE. Analyst consensus remains strongly bullish with 64.5% buy ratings and $481.63 price target representing 27% upside potential.
Teradyne presents compelling growth prospects fueled by AI-driven semiconductor testing demand and expanding robotics business. The stock trades at premium valuations (P/E 52.1, P/S 13.43) reflecting high growth expectations. Key risks include cyclical semiconductor industry exposure and execution challenges in scaling operations. Current technical positioning near pivot point ($384) suggests potential for breakout above resistance at $396 if earnings momentum continues through Q3 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
